{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:06:53Z","timestamp":1790057213841,"version":"4.0.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>\n                    Bisphosphonates (BPs) are clinically established bone-seeking agents that strongly bind to hydroxyapatite and selectively accumulate at sites of active bone remodeling. Among nitrogen-containing BPs, pamidronate (PAM) is widely used for the management of cancer-related bone complications and has also been associated with antiproliferative and pro-apoptotic effects in several tumor models. These properties make PAM an attractive ligand for the development of potential bone-targeted anticancer agents, particularly in the context of primary bone tumors and bone metastases, which are difficult to treat and are frequently associated with severe pain and skeletal complications. Platinum-based chemotherapeutics are effective anticancer agents, but their clinical use is often limited by poor tissue selectivity, systemic toxicity, and drug resistance. In this work, we report the synthesis and full characterization of two novel dinuclear platinum(II)\u2013PAM complexes in which PAM acts as a bridging ligand between two platinum centers containing either an oxaliplatin-derived [Pt(1\n                    <jats:italic>R<\/jats:italic>\n                    ,2\n                    <jats:italic>R<\/jats:italic>\n                    -diaminocyclohexane)]\n                    <jats:sup>2+<\/jats:sup>\n                    unit or a kiteplatin-derived [Pt(\n                    <jats:italic>cis<\/jats:italic>\n                    -1,4-diaminocyclohexane)]\n                    <jats:sup>2+<\/jats:sup>\n                    unit. The new compounds were characterized by multinuclear NMR spectroscopy and ESI-MS, and their chemical stability was investigated under physiological and mildly acidic conditions. Their reactivity toward DNA models and their\n                    <jats:italic>in vitro<\/jats:italic>\n                    antiproliferative activity against breast adenocarcinoma and osteosarcoma cells were also evaluated. Overall, these results highlight the influence of both the bisphosphonate scaffold and the diamine carrier ligand on the chemical and biological properties of dinuclear platinum(II) complexes, supporting their further investigation as potential agents for the treatment of bone malignancies.\n                  <\/jats:p>","DOI":"10.3389\/fchem.2026.1945537","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:41:10Z","timestamp":1790055670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Active targeting towards bone cancer and metastases by pamidronate-bridged dinuclear platinum(II) complexes"],"prefix":"10.3389","volume":"14","author":[{"given":"Anna Maria","family":"Di Cosola","sequence":"first","affiliation":[{"name":"Dipartimento di Chimica, Universit\u00e0 degli Studi di Bari Aldo Moro","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Barbanente","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica, Universit\u00e0 degli Studi di Bari Aldo Moro","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"D\u2019Anna","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Universit\u00e0 degli Studi di Palermo","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rubino","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Universit\u00e0 degli Studi di Palermo","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Terenzi","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Universit\u00e0 degli Studi di Palermo","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Niso","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia-Scienze del Farmaco, Universit\u00e0 degli Studi di Bari Aldo Moro","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Margiotta","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica, Universit\u00e0 degli Studi di Bari Aldo Moro","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/ma18051043","article-title":"Exploring selenium-functionalized hydroxyapatite using organic selenocystine for antitumor applications","volume":"18","author":"Barbanente","year":"","journal-title":"Materials"},{"key":"B2","doi-asserted-by":"publisher","first-page":"112916","DOI":"10.1016\/j.jinorgbio.2025.112916","article-title":"New oxaliplatin-zoledronate derivatives with potential antitumor activity towards bone tumors and metastases","volume":"270","author":"Barbanente","year":"","journal-title":"J. Inorg. Biochem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10100","DOI":"10.1039\/d5ra09348a","article-title":"Development of dual acting selenium-doped hydroxyapatite nanoparticles with platinum-bisphosphonate complexes for bone cancer therapy","volume":"16","author":"Barbanente","year":"2026","journal-title":"RSC Adv."},{"key":"B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11914-016-0315-2","article-title":"The bone microenvironment: a fertile soil for tumor growth","volume":"14","author":"Buenrostro","year":"2016","journal-title":"Curr. Osteoporos. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3892\/ol.2012.723","article-title":"Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells","volume":"4","author":"Chang","year":"2012","journal-title":"Oncol. Lett."},{"key":"B6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13569-016-0046-2","article-title":"Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients","volume":"6","author":"Conry","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctrv.2014.12.001","article-title":"Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment","volume":"41","author":"Criscitiello","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"B9","first-page":"193","article-title":"A rapid method for the synthesis of Cis-[Pt(NH3)2Cl2]","volume":"8","author":"Dhara","year":"1970","journal-title":"Indian J. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"106939","DOI":"10.1016\/j.ejps.2024.106939","article-title":"Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies","volume":"203","author":"Elmorsy","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S8756-3282(03)00223-0","article-title":"Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis","volume":"33","author":"Evdokiou","year":"2003","journal-title":"Bone"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1039\/jr9640004587","article-title":"The electrolyte type of ionized complexes","volume":"167","author":"Feltham","year":"1964","journal-title":"J. Chem. Soc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1471-2474-12-146","article-title":"Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro","volume":"12","author":"Fu","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1021\/jm0308040","article-title":"Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N,N-Bis(phosphonomethyl)glycine ligand","volume":"46","author":"Galanski","year":"2003","journal-title":"J. Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/cmdc.201400061","article-title":"Trans, cis, cis-Bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine) platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer","volume":"9","author":"Gandin","year":"2014","journal-title":"ChemMedChem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1039\/D4DT00245H","article-title":"Investigating the anticancer potential of 4-phenylthiazole derived Ru(II) and Os(II) metalacycles","volume":"53","author":"Getreuer","year":"2024","journal-title":"Dalton Trans."},{"key":"B17","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.1039\/C6DT01414C","article-title":"Platinum(IV) anticancer prodrugs \u2013 hypotheses and facts","volume":"45","author":"Gibson","year":"2016","journal-title":"Dalton Trans."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/0008-5472.CAN-15-0204","article-title":"Activation of hematopoietic stem\/progenitor cells promotes immunosuppression within the pre\u2013metastatic niche","volume":"76","author":"Giles","year":"2016","journal-title":"Cancer Res."},{"key":"B19","first-page":"65","article-title":"Bisphosphonates: prevention of bone metastases in breast cancer","volume-title":"Prevention of Bone Metastases. Recent Results in Cancer Research","author":"Gnant","year":"2012"},{"key":"B20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/cbic.201000724","article-title":"Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin\/oxaliplatin cytotoxicity","volume":"12","author":"Graf","year":"2011","journal-title":"ChemBioChem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1002\/ejoc.200601067","article-title":"Syntheses of phosphonic esters of alendronate, pamidronate and neridronate","volume":"2007","author":"Gu\u00e9nin","year":"2007","journal-title":"Eur. J. Org. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1021\/la703381h","article-title":"Adsorption and conformational change of myoglobin on biomimetic hydroxyapatite nanocrystals functionalized with alendronate","volume":"24","author":"Iafisco","year":"2008","journal-title":"Langmuir"},{"key":"B24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.poly.2013.10.003","article-title":"The crystal structure of oxaliplatin: a case of overlooked pseudo symmetry","volume":"67","author":"Johnstone","year":"2014","journal-title":"Polyhedron"},{"key":"B25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1124\/mol.111.077321","article-title":"Anticancer activity of methyl-substituted oxaliplatin analogs","volume":"81","author":"Jungwirth","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF02983531","article-title":"Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines","volume":"79","author":"Kimura","year":"2004","journal-title":"Int. J. Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.tips.2015.04.006","article-title":"New therapeutic targets for cancer bone metastasis","volume":"36","author":"Krzeszinski","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"7958","DOI":"10.3390\/ijms26167958","article-title":"Research progress of platinum-based complexes in lung cancer treatment: mechanisms, applications, and challenges","volume":"26","author":"Liang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1021\/jm3006838","article-title":"Revisiting [PtCl2(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer","volume":"55","author":"Margiotta","year":"2012","journal-title":"J. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"10329","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (everolimus): pivotal role of the prenylation process","volume":"70","author":"Moriceau","year":"2010","journal-title":"Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41573-023-00774-7","article-title":"Artificial intelligence for natural product drug discovery","volume":"22","author":"Mullowney","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1038\/s41598-020-62039-2","article-title":"Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity","volume":"10","author":"Nadar","year":"2020","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"100088","DOI":"10.1016\/j.mtbio.2020.100088","article-title":"Bone tumor\u2013targeted delivery of theranostic 195mPt-bisphosphonate complexes promotes killing of metastatic tumor cells","volume":"9","author":"Nadar","year":"2021","journal-title":"Mat. Today Bio"},{"key":"B36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1248\/cpb.59.710","article-title":"Dialkyl bisphosphonate platinum (II) complex as a potential drug for metastatic bone tumor","volume":"59","author":"Nakatake","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"B37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3579","article-title":"Disrupting proton dynamics and energy metabolism for cancer therapy","volume":"13","author":"Parks","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9689","DOI":"10.1039\/c2dt30712j","article-title":"Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs","volume":"41","author":"Piccinonna","year":"2012","journal-title":"Dalton Trans."},{"key":"B39","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1021\/acs.jmedchem.3c01093","article-title":"Discovery of novel aminobutanoic acid-based ASCT2 inhibitors for the treatment of non-small-cell lung cancer","volume":"67","author":"Qin","year":"2024","journal-title":"J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"113091","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1021\/ic702202x","article-title":"Conformer distribution in (cis-1,4-DACH)bis(guanosine-5\u2032-phosphate)platinum(II) adducts: a reliable model for DNA adducts of antitumoral cisplatin","volume":"47","author":"Ranaldo","year":"2008","journal-title":"Inorg. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"B43","first-page":"109","article-title":"Bisphosphonates: prevention of bone metastases in prostate cancer","volume-title":"Prevention of Bone Metastases. Recent Results in Cancer Research","author":"Saad","year":"2012"},{"key":"B44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/bcr412","article-title":"The role of bisphosphonates in breast cancer: direct effects of bisphosphonates on breast cancer cells","volume":"4","author":"Senaratne","year":"2001","journal-title":"Breast Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"100205","DOI":"10.1016\/j.crphar.2024.100205","article-title":"Unveiling the chemotherapeutic potential of two platinum(IV) complexes in skin cancer: in vitro and in vivo insights","volume":"7","author":"Slika","year":"2024","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"14659","DOI":"10.18632\/oncotarget.7406","article-title":"Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia","volume":"7","author":"Syu","year":"2016","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1039\/b908652h","article-title":"Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases","volume":"4847","author":"Torres Martin de Rosales","year":"2009","journal-title":"Chem. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2005.09.022","article-title":"Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma","volume":"44","author":"Wada","year":"2006","journal-title":"J. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3110","article-title":"Dysregulated pH: a perfect storm for cancer progression","volume":"11","author":"Webb","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fcell.2020.00076","article-title":"RANKL\/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies","volume":"8","author":"Wu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1021\/acs.jmedchem.0c02044","article-title":"Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site","volume":"64","author":"Xi","year":"2021","journal-title":"J. Med. Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1039\/b922222g","article-title":"Platinum(II) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity","volume":"46","author":"Xue","year":"2010","journal-title":"Chem. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/metabo13070796","article-title":"Cancer metabolism: the role of ROS in DNA damage and induction of apoptosis in cancer cells","volume":"13","author":"Zhao","year":"2023","journal-title":"Metabolites"},{"key":"B54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1021\/acscentsci.5c01473","article-title":"From prompt to drug: toward pharmaceutical superintelligence","volume":"12","author":"Zhavoronkov","year":"2026","journal-title":"ACS Cent. Sci."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1945537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:41:12Z","timestamp":1790055672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1945537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":54,"alternative-id":["10.3389\/fchem.2026.1945537"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2026.1945537","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1945537"}}